{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:33:05Z","timestamp":1790940785236,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore whether the frequencies and functional molecules expression of Natural Killer cells (NK cells) are related to hepatitis B surface antigen (HBsAg) disappearance in hepatitis B e envelope antigen (HBeAg)-positive patients with chronic hepatitis B (CHB) throughout peginterferon alpha-2a (PEG-IFN \u03b1-2a) treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective research, HBeAg-positive patients with CHB received PEG-IFN \u03b1-2a treatment, completing 4-year follow-up. After PEG-IFN \u03b1-2a treatment, undetectable HBV DNA, HBsAg loss, and HBeAg disappearance were defined as functional cure. Proportions of NK, CD56<jats:sup>dim<\/jats:sup>, CD56<jats:sup>bright<\/jats:sup>, NKp46<jats:sup>+<\/jats:sup>, NKp46<jats:sup>dim<\/jats:sup>, NKp46<jats:sup>high<\/jats:sup>, and interferon alpha receptor 2 (IFNAR2)<jats:sup>+<\/jats:sup> NK cells, and the mean fluorescence intensity (MFI) of NK cell surface receptors IFNAR2 and NKp46 were detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>66 patients were enrolled into the study in which 17 patients obtained functional cure. At baseline, hepatitis B virus desoxyribose nucleic acid (HBV DNA) titer in patients with functional cure was remarkably lower than that in Non-functional cure group. Compared with baseline, HBV DNA levels, HBsAg levels, and HBeAg levels significantly declined at week 12 and 24 of therapy in patients with functional cure. At baseline, the negative correlation between CD56<jats:sup>bright<\/jats:sup> NK% and HBV DNA and the negative correlation between CD56<jats:sup>dim<\/jats:sup> NK% and HBV DNA was showed; CD56<jats:sup>bright<\/jats:sup> NK% and IFNAR2 MFI in patients with functional cure were remarkably higher than those in patients without functional cure. After therapy, CD56<jats:sup>bright<\/jats:sup> NK% and NKp46<jats:sup>high<\/jats:sup> NK% in patients with functional cure were higher than those in patients without functional cure. In Functional cure group, after 24 weeks of treatment NK%, CD56<jats:sup>bright<\/jats:sup> NK%, IFNAR2 MFI weakly increased, and NKp46<jats:sup>high<\/jats:sup> NK% and NKp46 MFI significantly increased, meanwhile, CD56<jats:sup>dim<\/jats:sup> NK% and NKp46<jats:sup>dim<\/jats:sup> NK% decreased. Only NKp46 MFI increased after therapy in patients without functional cure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The lower HBV DNA load and the higher CD56<jats:sup>bright<\/jats:sup> NK% before therapy, and the higher the post-treatment CD56<jats:sup>bright<\/jats:sup> NK%, IFNAR2 MFI, NKp46<jats:sup>high<\/jats:sup> NK%, the easier to achieve functional cure.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1067362","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T06:04:38Z","timestamp":1669010678000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN \u03b1-2a therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Weihua","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis b virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B2","article-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, , 2021: Accountability for the global health sector strategies 2016\u20132021: Actions for impact","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"311\u22125","DOI":"10.1007\/s12072\u2212007\u22129002\u22129","article-title":"Spontaneous relapse of hepatitis in inactive HBsAg carriers","volume":"1","author":"Chu","year":"2007","journal-title":"Hepatol Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23464","article-title":"Clearance of hepatitis b surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis b virus","volume":"51","author":"Simonetti","year":"2010","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.04.006","article-title":"Drugs in the pipeline for HBV","volume":"23","author":"Lopatin","year":"2019","journal-title":"Clin Liver Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31408","article-title":"Have the starting lineup of five for hepatitis b virus covalently closed circular DNA synthesis been identified","volume":"72","author":"Zhao","year":"2020","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis b","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis b cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis b surface antigen in patients with chronic hepatitis b","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/hep4.1436","article-title":"Durability of hepatitis b surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis b","volume":"4","author":"Lok","year":"2019","journal-title":"Hepatol Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis b s antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14629","article-title":"Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis b focusing on hepatitis b surface antigen clearance","volume":"47","author":"Qiu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2178143","article-title":"The characteristics of natural killer cells in chronic hepatitis b patients who received PEGylated-interferon versus entecavir therapy","volume":"2021","author":"Cao","year":"2021","journal-title":"BioMed Res Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891424","article-title":"Expression of functional molecule on plasmacytoid dendritic cells is associated with HBsAg loss in HBeAg-positive patients during PEG-IFN \u03b1-2a treatment","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis b is associated with liver damage and HBsAg loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cei.12597","article-title":"Activated natural killer cells accelerate liver damage in patients with chronic hepatitis b virus infection","volume":"180","author":"Zheng","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2015.05.006","article-title":"Natural killer cells in hepatitis b virus infection","volume":"19","author":"Wu","year":"2015","journal-title":"Braz J Infect Dis 19"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21508","article-title":"Markers and function of human NK cells in normal and pathological conditions","volume":"92","author":"Del Zotto","year":"2017","journal-title":"Cytom Part B Clin Cytom"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00937","article-title":"IFNAR2 deficiency causing dysregulation of NK cell functions and presenting with hemophagocytic lymphohistiocytosis","volume":"11","author":"Passarelli","year":"2020","journal-title":"Front Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.19324","article-title":"Incubation phase of acute hepatitis b in man: dynamic of cellular immune mechanisms","volume":"32","author":"Webster","year":"2000","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit561","article-title":"Compromised function of natural killer cells in acute and chronic viral hepatitis","volume":"209","author":"Lunemann","year":"2014","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049135","article-title":"Natural killer cells are characterized by the concomitantly increased interferon-\u03b3 and cytotoxicity in acute resolved hepatitis b patients","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.20411\/pai.v3i1.228","article-title":"ADCC-mediated CD56dim NK cell responses are associated with early HBsAg clearance in acute HBV infection","volume":"3","author":"Yu","year":"2018","journal-title":"Pathog Immun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.06.015","article-title":"Hepatitis b virus antigens impair NK cell function","volume":"38","author":"Yang","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14885","article-title":"The impact of hepatitis b surface antigen on natural killer cells in patients with chronic hepatitis b virus infection","volume":"41","author":"Du","year":"2021","journal-title":"Liver Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147643","article-title":"HBsAg dampened STING associated activation of NK cells in HBeAg-negative CHB patients","volume":"22","author":"Zheng","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK cell exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab216","article-title":"Pegylated interferon-\u03b1 (IFN-\u03b1) enhances the inhibitory effect of natural killer cells on regulatory T cells via IFN-\u03b3 in chronic hepatitis b","volume":"224","author":"Yuan","year":"2021","journal-title":"J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158297","article-title":"Pegylated interferon \u03b1-2a triggers NK-cell functionality and specific T-cell responses in patients with chronic HBV infection without HBsAg seroconversion","volume":"11","author":"Bruder Costa","year":"2016","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005788","article-title":"Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis b viral load suppression","volume":"12","author":"Gill","year":"2016","journal-title":"in Vivo. PLoS Pathog"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12946","article-title":"CD56bright natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a","volume":"25","author":"Shi","year":"2018","journal-title":"J Viral Hepat"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/1753425920942580","article-title":"Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy","volume":"26","author":"Cao","year":"2020","journal-title":"Innate Immun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2015.09.004","article-title":"Natural killer cells in viral hepatitis","volume":"1","author":"Rehermann","year":"2015","journal-title":"Cell Mol Gastroentrol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2010.02332.x","article-title":"Natural killer cells in viral hepatitis: facts and controversies","volume":"40","author":"Mondelli","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12967-017-1318-1","article-title":"Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment","volume":"15","author":"Li","year":"2017","journal-title":"J Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24326","article-title":"Serum hepatitis b surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis b-associated hepatocellular carcinoma","volume":"88","author":"Wang","year":"2016","journal-title":"J Med Virol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2010.07.009","article-title":"Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis b","volume":"54","author":"Tjwa","year":"2010","journal-title":"J Hepatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.antiviral.2017.01.00","article-title":"NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection","volume":"140","author":"Groen","year":"2017","journal-title":"Antiviral Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000360941","article-title":"Interferon therapy of chronic hepatitis b","volume":"57","author":"Brunetto","year":"2014","journal-title":"Intervirology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe4627","article-title":"IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs","volume":"14","author":"Shemesh","year":"2021","journal-title":"Sci Signal"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135874","article-title":"Natural killer p46 controls hepatitis b virus replication and modulates liver inflammation","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1067362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T06:04:41Z","timestamp":1669010681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1067362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2022.1067362"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1067362","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"article-number":"1067362"}}